Zevalin Data to be Presented at ASH 2008 ( SEATTLE Dec. 4 /- Cell Therapeutics I...)

Zevalin Data to be Presented at ASH 2008

Date:12/3/2008

SEATTLE, Dec. 4 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced presentations or posters of interest related to Zevalin(R) (ibritumomab tiuxetan) to be presented at the 50th Annual Meeting of the American Society of Hematology (ASH), December 5-9, 2008 in San Francisco.

In addition, James Bianco, M.D., CEO of Cell Therapeutics will participate in a panel hosted by Biotechnology Industry Organization and Gerson Lehrman Group(R), "Gerson Lehrman Group Innovators: Non-Hodgkin's Lymphoma," on Saturday, December 6.

CTI and Spectrum announced on November 26, 2008 that they have entered into an agreement to form a joint venture, RIT Oncology LLC, to commercialize and develop Zevalin in the United States.

Presentation/
Date/Time Abstract # Poster # Title
Saturday,
Dec. 6, 2008
5:30-7:30 PM 1144 Poster I-249 Radioimmunotherapy (90Y-
Zevalin(R)) Combined with
BEAM Conditioning Regimen and
Autologous Stem Cell
Transplantation for the
Treatment of Non Hodgkin
Lymphomas: Results of An
Italian Multicenter Study

Sunday
Dec. 7, 2008
6:00-8:00 PM 1959 Poster II-53 Radioimmunotherapy with
Yttrium-90-Ibritumomab
Tiuxetan as Part of a Reduced
Intensity Conditioning
Regimen for Allogeneic
Hematopoietic Cell

'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved
0

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
2. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
3. Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
4. Zevalin Revenues Lead Cell Therapeutics, Inc.s First Quarter 2008 Financial Results
5. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
6. Nautica Malibu Triathlon Presented by Toyota Raises $718,000 for Childrens Hospital Los Angeles Pediatric Cancer Research
7. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
8. Success of Shape Up Somerville childhood obesity intervention to be presented
9. Survival data presented from phase II study of hormone-resistant prostate cancer patients
10. Special Olympics Special Spirit in China Award Of Excellence Presented to Dedicated Friends of Special Olympics and City of Shanghai
11. UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Presented at American Society for Dermatologic Surgery Annual Meeting

Post Your Comments:

Zevalin Data to be Presented at ASH 2008( SEATTLE Dec. 4 /- Cell Therapeutics I...),Health